{"favorite_id": 2143, "calc_type": "", "dosing": false, "full_title_en": "Sokal Index for Chronic Myelogenous Leukemia (CML)", "short_title_en": "Sokal Score", "medium_description_en": "Predicts survival of CML based on clinical and lab information.", "short_description_en": "CML survival.", "before_use": "", "instructions_en": "<p>Use to predict prognosis at the time of CML diagnosis, before starting treatment.</p>", "purpose_en": ["Prognosis"], "disease_en": ["CML", "Cancer", "Chemotherapy", "Hematologic Malignancy", "Leukemia/Lymphoma"], "specialty_en": ["Hematology and Oncology", "Palliative Care/Hospice"], "chief_complaint_en": ["Dizziness", "Lymphadenopathy"], "system_en": ["Hematologic", "Oncologic"], "search_abbreviation_en": ["cml", "blast", "plt", "platelets"], "slug": "sokal-index-chronic-myelogenous-leukemia-cml", "seo": {"meta_description_en": "The Sokal Index for CML predicts survival of CML based on clinical and lab information.", "keywords_en": "cml score, sokal cancer score, sokal score, sokal index, sokal cml index, sokal index for cml, plt cml, spleen size cml, myeoblasts cml, Chronic Myeloid leukemia"}, "content": {"how_to_use": {"use_case_en": "<p>In the US, the Sokal Score can be used to determine risk and decide on therapy based on the <a href=\"https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf\" target=\"_blank\">NCCN guidelines for CML</a>. While the EUTOS score is easier to calculate and more accurately identifies high risk patients in the era of tyrosine kinase inhibitors, it has not been adopted by the NCCN guidelines. </p>", "pearls_pitfalls_en": "<ul> <li>The Sokal Index, also referred to as the Sokal Score, was developed using patients treated&nbsp;in the pre-tyrosine kinase inhibitor era and thus can not necessarily be applied today. Survival outcomes have drastically improved since then.</li> <li>Although scores are stratified into low, intermediate, and high risk, some studies have shown that low and intermediate risk have similar outcomes.</li> <li>Some advocate combining the Sokal and <calculator id=\"3906\">EUTOS</calculator> Scores for better predictive value.</li> </ul>", "why_use_en": "<ul> <li><a href=\"https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf\" target=\"_blank\">NCCN guidelines</a> for CML treatment recommend use of the Sokal and Hasford Scores over <calculator id='3906'>EUTOS</calculator> for clinical risk stratification. </li> <li>The Sokal Score is also preferentially used in clinical trials so that comparisons can be made to prior trials. </li> </ul>"}, "next_steps": {"advice_en": "<p>Whether the patient meets milestones for cytogenetic and molecular response is more predictive of outcome once therapy is started.</p>", "management_en": "<p>Although the Sokal Score has limited usefulness outside of clinical trials today, in general, low and intermediate risk patients can be started on standard dose imatinib, and high risk patients should be considered for newer generation TKIs or be monitored more closely to ensure complete molecular response.</p>", "critical_actions_en": "<p>Can only be applied in a newly-diagnosed patient prior to starting therapy.</p>"}, "about": {"formula_en": "<p>Sokal Score = exp([0.0116 &times; (age in years &ndash; 43.4)] + [0.0345 &times; (spleen size in cm &ndash; 7.51)] + [0.188 x ((platelets in 10<sup>9</sup>/L / 700)<sup>2</sup> &ndash; 0.563)] + [0.0887 &times; (blasts in % &ndash; 2.10)])</p>", "more_info_en": "<p>Interpretation:</p> <div class=\"table-responsive\"> <table class=\"table table-bordered\"> <tbody> <tr> <td> <p><strong>Risk Group</strong></p> </td> <td> <p><strong>Sokal Score</strong></p> </td> <td> <p><strong>2-year Survival</strong></p> </td> <td> <p><strong>Median Survival </strong></p> </td> </tr> <tr> <td> <p>Low</p> </td> <td> <p>&lt;0.8</p> </td> <td> <p>90%</p> </td> <td> <p>5 years</p> </td> </tr> <tr> <td> <p>Intermediate</p> </td> <td> <p>0.8\u20131.2</p> </td> <td> <p>65-90%</p> </td> <td> <p>2.5-5 years</p> </td> </tr> <tr> <td> <p>High</p> </td> <td> <p>&gt;1.2</p> </td> <td> <p>65%</p> </td> <td> <p>2.5 years</p> </td> </tr> </tbody> </table> </div>", "evidence_based_medicine_en": "<p>The original <a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1731441/pdf/v054p00491.pdf\" target=\"_blank\">derivation study</a> included 813 European and American patients treated before imatinib was available. The <a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1731441/pdf/v054p00491.pdf\" target=\"_blank\">validation study</a> was done during the era of interferon treatment and showed that, even then, the Sokal Score was no longer predictive, and the Hasford Score was a better predictor of survival. Outcomes have significantly improved after the use of imatinib and led to the development of a new score called the EUTOS Score. <br>There are two major studies (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23540886\" target=\"_blank\">Uz 2013</a>, Yahng 2012) suggesting the EUTOS Score outperforms the Sokal Score and one study (<a href=\"http://ascopubs.org/doi/full/10.1200/jco.2011.37.6962\" target=\"_blank\">Marin 2011</a>) showing the converse.</p>", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/6584184", "text": "Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 1984; 63: 789-99."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/23540886 ", "text": "Uz B, Buyukasik Y, Atay H, et al. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology. 2013;18(5):247-52."}, {"href": "", "text": "Yahng SA, Jang EJ, Choi SY, et al. Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each prognostic model: a single center data analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood 2012;120:Abstract 2794."}, {"href": "http://ascopubs.org/doi/full/10.1200/jco.2011.37.6962   \t", "text": "Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944\u20135. "}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/24450386 ", "text": "Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105-9."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/26416462 ", "text": "Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56."}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1731441/pdf/v054p00491.pdf ", "text": "Thomas M, Irving J, Lennard A, Proctor S, Taylor P. Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia. Journal of Clinical Pathology. 2001;54(6):491-493. doi:10.1136/jcp.54.6.491."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Justin Taylor, MD, is an assistant professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He is board certified in internal medicine and medical oncology. He completed his internship and residency at Brigham and Women\u2019s Hospital in Boston. His clinical and research focuses are on the basic biology and translational significance of somatic genetic mutations in hematologic malignancies.</p>", "firstName": "Justin", "img": "https://cdn-web-img.mdcalc.com/people/justin-taylor.jpg", "lastName": "Taylor", "name": "Justin Taylor, MD", "target": "justin-taylor", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"id": 273, "name": "Dr. Joseph E. Sokal", "qa_en": "", "approved": false, "priority": 0, "creator_info": {"about_en": "<p>Joseph E. Sokal, MD, (d. 1988) was a researcher in cancer treatment and a scholar in residence at Duke University. Previously, he was chief cancer research clinician at Roswell Park Memorial Institute in Buffalo and an assistant professor at Yale University.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-joseph-e-sokal.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Sokal+JE%5BAuthor%5D"}}], "reviewer": {"expert_name": [{"name": "Michael Mauro, MD"}]}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"label_en": "Age", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "age", "unit": "age", "type": "textbox", "unit_info": {"name": "Age", "conversion": 1, "error_min": 0.001, "error_max": 120, "warn_min": 0.1, "warn_max": 100, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "years", "units_us": "years"}}, {"label_en": "Spleen size", "conditionality": "", "default": null, "tips_en": "Maximum distance palpable below costal margin", "optional": false, "name": "spl", "unit": "spleen", "type": "textbox", "unit_info": {"name": "Max distance of spleen from costal margin", "conversion": 0.39370079, "error_min": 0, "error_max": 20, "warn_min": 0, "warn_max": 10, "normal_max_si": 5, "normal_min_si": 0, "normal_min_us": 0, "units_si": "in", "units_us": "cm", "normal_max_us": 12.7}}, {"label_en": "Platelet count", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "plt", "unit": "plt", "type": "textbox", "unit_info": {"name": "Platelet Count", "conversion": 1, "error_min": 1, "error_max": 3200, "warn_min": 10, "warn_max": 750, "normal_max_si": 350, "normal_min_si": 150, "normal_min_us": 150, "units_si": "\u00d7 10\u2079/L", "units_us": "\u00d7 10\u00b3/\u00b5L", "normal_max_us": 350}}, {"label_en": "% myeloblasts in peripheral blood", "conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "blasts", "unit": "myeloblasts", "type": "textbox", "unit_info": {"name": "% Myeloblasts", "conversion": 1, "error_min": -0.01, "error_max": 100.01, "warn_min": 0, "warn_max": 100, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "%", "units_us": "%"}}], "md5": "", "cmeVersion": null, "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 3906, "short_title_en": "EUTOS Score", "slug": "eutos-score-for-chronic-myelogenous-leukemia-cml"}, {"calcId": 2321, "short_title_en": "GELF Criteria for Follicular Lymphoma", "slug": "groupe-detude-des-lymphomes-folliculaires-gelf-criteria"}, {"calcId": 2320, "short_title_en": "FLIPI for Follicular Lymphoma", "slug": "follicular-lymphoma-international-prognostic-index-flipi"}]}